Compare DuPont de Nemours Inc (DD) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Intuitive Surgical, Inc. — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.12B), while Intuitive Surgical, Inc. trades at $400 (market cap $138.97B). The key difference: Intuitive Surgical, Inc. is far larger — about 7.3× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| DD | ISRG | |
|---|---|---|
Market Cap | $19.12B | $138.97B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $592.85 |
52-Week Low | $90.24 | $332.02 |
Enterprise Value | $20.50B | $133.76B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
Intuitive Surgical (ISRG) trades at $378.81, up 1.36% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bullish technical signals despite premium valuations (P/E 43.44, P/S 12.35), supported by robust revenue growth reaching $10.06B in 2025 and expanding profit margins of 28.45%. Recent news highlights da Vinci 5 adoption driving procedure growth beyond urology.
Outlook remains positive with 68% analyst buy ratings and $519.05 price target suggesting 37% upside. Key risks include competitive pressure from Medtronic/J&J robots and potential U.S. procedure softness. The combination of durable demand and innovation pipeline supports long-term growth potential for MedTech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
